Trial Profile
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF A FOUR-WEEK TREATMENT WITH YM758 IN SUBJECTS WITH STABLE ANGINA.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2017
Price :
$35
*
At a glance
- Drugs YM 758 (Primary)
- Indications Angina pectoris
- Focus Adverse reactions
- Acronyms IRIS
- Sponsors Astellas Pharma Europe Ltd
- 23 Feb 2017 New trial record